Edwards Lifesciences Reports Strong Q2 Results with Raised Full-Year Guidance
Edwards Lifesciences (NYSE:EW) reported second-quarter earnings that exceeded expectations, posting sales of $1.74 billion and adjusted EPS of $0.78. The company attributed the strong performance to growth across its TAVR, mitral/tricuspid therapies, and surgical products segments. TAVR was a key driver with global sales reaching $1.3 billion in Q2, up 10.5% year-over-year. Management raised full-year TAVR guidance to 8-9%, citing sustained clinical momentum and the continued adoption of its SAPIEN platform. Transcatheter mitral and tricuspid therapies (TMTT) also showed robust growth with sales rising 44.8% to $195.9 million, driven by strong performance from multiple products including PASCAL, EVOQUE, and SAPIEN M3. Edwards increased its full-year total company sales guidance to a range of 10-11%, up from the previous estimate of 9-11%. The adjusted EPS outlook remains unchanged at $2.95-$3.05 for fiscal year 2026.
Tickers: $EW